{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:20:17Z","timestamp":1783092017272,"version":"3.54.6"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["260931"],"award-info":[{"award-number":["260931"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010600","name":"Tays","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010600","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015230","name":"Fondation Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euros.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:22:19Z","timestamp":1778851339000},"page":"107-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparison of the Swedish and Finnish Centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC)"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5808-1809","authenticated-orcid":false,"given":"Marianne","family":"M\u00e5nsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Talala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Hugosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.04.008_b0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-year Follow-up of the European Randomized study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.04.008_b0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.04.008_b0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.eururo.2019.04.007","article-title":"The impact of design and performance in prostate-specific antigen screening: differences between ERSPC centers","volume":"76","author":"Heijnsdijk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.04.008_b0020","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/cncr.31178","article-title":"The efficacy of prostate-specific antigen screening: impact of key components in the ERSPC and PLCO trials","volume":"124","author":"de Koning","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2026.04.008_b0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1078-0432.CCR-15-0941","article-title":"Absolute effect of prostate cancer screening: balance of benefits and harms by center within the European randomized study of prostate cancer screening","volume":"22","author":"Auvinen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2026.04.008_b0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0969141316652174","article-title":"Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial","volume":"24","author":"Hakama","year":"2017","journal-title":"J Med Screen"},{"key":"10.1016\/j.euros.2026.04.008_b0035","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the Goteborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.04.008_b0040","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djt038","article-title":"Prostate cancer mortality in the Finnish randomized screening trial","volume":"105","author":"Kilpel\u00e4inen","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euros.2026.04.008_b0045","first-page":"101","article-title":"The relative survival rate: a statistical methodology","volume":"6","author":"Ederer","year":"1961","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.euros.2026.04.008_b0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.euros.2026.04.008_b0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2017.01.048","article-title":"Estimate of opportunistic prostate specific antigen testing in the Finnish randomized study of screening for prostate cancer","volume":"198","author":"Kilpel\u00e4inen","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.04.008_b0060","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/ijc.30924","article-title":"Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975\u20132013","volume":"141","author":"Kv\u00e5le","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euros.2026.04.008_b0065","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/JU.0000000000002835","article-title":"Prostate specific antigen and biopsy contamination in the G\u00f6teborg-1 randomized, population-based, prostate cancer screening trial","volume":"208","author":"Stinesen Kollberg","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.04.008_b0070","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bju.13505","article-title":"Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC)","volume":"118","author":"Bokhorst","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.04.008_b0075","doi-asserted-by":"crossref","unstructured":"Remmers S, Talala K, Roobol MJ, et al. Effects of causal and noncausal components of screening on prostate cancer mortality: A mediation analysis from the Dutch, Finnish, and Swedish centers of the European randomized study of screening for prostate cancer. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2025.12.004.","DOI":"10.1016\/j.euo.2025.12.004"},{"key":"10.1016\/j.euros.2026.04.008_b0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.euf.2017.07.007","article-title":"Impact of prostatic-specific antigen threshold and screening interval in prostate cancer screening outcomes: comparing the Swedish and Finnish European randomised study of screening for prostate cancer centres","volume":"5","author":"Saarim\u00e4ki","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.04.008_b0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.04.008_b0090","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.04.008_b0095","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.purol.2020.02.011","article-title":"Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"30","author":"Villers","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.euros.2026.04.008_b0100","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bju.14580","article-title":"Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial","volume":"123","author":"Pinsky","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.04.008_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077738","article-title":"Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study","volume":"386","author":"Vaccarella","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.euros.2026.04.008_b0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eururo.2022.10.006","article-title":"Young age on starting prostate-specific antigen testing is associated with a greater reduction in prostate cancer mortality: 24-year follow-up of the G\u00f6teborg randomized population-based prostate cancer screening trial","volume":"83","author":"Carlsson","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.04.008_b0115","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ijc.32129","article-title":"Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: analysis of the Finnish randomized study of screening for prostate cancer","volume":"145","author":"Lindberg","year":"2019","journal-title":"Int J Cancer"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326004933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326004933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:41:40Z","timestamp":1783089700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326004933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"alternative-id":["S2666168326004933"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.04.008","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the Swedish and Finnish Centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC)","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}